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Candesartan has been reported to have a protective effect on cerebral ischemia in vivo 
and in human ischemic stroke. We studied the direct effects of candesartan on 
blood-brain barrier (BBB) function with our in vitro monolayer model generated using rat 
brain capillary endothelial cells (RBEC). The in vitro BBB model was subjected to 
normoxia or 6-h oxygen glucose deprivation (OGD)/24-h reoxygenation, with or without 
candesartan. 6-h OGD/24-h reoxygenation decreased transendothelial electrical 
resistance (TEER) and increased the endothelial permeability for sodium fluorescein in 
RBEC monolayers. Candesartan (10 nM) improved RBEC barrier dysfunction induced 
by 6-h OGD/24-h reoxygenation. Immunostaining and immunoblotting analysis 
indicated that the effect of candesartan on barrier function under 6-h OGD/24-h 
reoxygenation was not related to the expression levels of tight junction proteins. 
However, candesartan affected RBEC morphological changes induced by 6-h 
OGD/24-h reoxygenation. We analyzed oxidative stress and cell viability using chemical 
reagents. Candesartan improved cell viability following 6-h OGD/24-h reoxygenation, 
whereas candesartan had no effect on oxidative stress. These results show that 
candesartan directly improves cell function and viability of brain capillary endothelial 
cells under OGD/reoxygenation, suggesting that the protective effects of candesartan 




The renin-angiotensin system (RAS) plays an important role in the regulation of fluid 




as hypertension, heart failure, and stroke (Zaman et al. 2002; Schmieder et al. 2007). 
The angiotensin II (Ang II) has various influences on vascular systems via its specific 
receptors (AT1 and AT2) under pathological and physiological conditions. AT1 receptor 
blockers (ARBs) specifically inhibit the diverse physiological effects mediated by the AT1 
receptor. Thus, AT1 receptor blockade is highly relevant to the treatment of 
cardiovascular disease. ARBs not only have strong blood pressure-lowering effects in 
hypertensive patients, but also induce regression of left ventricular hypertrophy and 
decrease cardiovascular morbidity and mortality in patients with heart failure (Cohn and 
Togoni 2001; Lindholm et al. 2002; Pfeffer et al. 2003). 
Cerebral ischemia, a leading cause of death and disability, induces cerebral vascular 
and neuronal damage. Several recent clinical trials have shown the efficacy of ARBs in 
primary and secondary prevention of stroke in patients with hypertension and/or 
elevated cardiovascular risk (Dahlöf B et al. 2002; Schrader et al. 2003; Ogihara et al. 
2008). In addition, treatment of patients with the ARB candesartan during the acute 
phase of cerebral ischemia produced beneficial effects on cerebrovascular events that 
were independent of alterations in blood pressure (Schrader et al. 2003). As the RAS 
components exist in vascular systems as well as in the central nervous system, 
candesartan appears to affect both vascular and neural systems. Indeed, several 
reports have indicated that candesartan improves neuronal damage and cognitive 
impairment caused by cerebral ischemia (Lu et al. 2005; Skoog et al. 2005). In contrast, 
the consequences of AT1 receptor blockade on the cerebral vascular system are 
controversial. Although AT1 receptor blockade decreased vascular hyperpermeability 
induced by experimental stroke (Kozak et al. 2009), Wosik et al. (2007) reported that 




conditions. Thus, we aimed to investigate the effects of AT1 receptor blockade on BBB 
barrier function under normal and hypoxic conditions. 
Brain capillary endothelial cells form the anatomical basis of the BBB and have a highly 
specialized system for regulating the passage of substances from the blood into the 
brain parenchyma (Engelhardt 2003; Abbott 2005). As the brain capillary endothelial 
cells are tightly sealed with adhesion molecules present in tight junctions and adherens 
junctions, vascular damage induced by cerebral stroke results in the development of 
brain edema. In addition, BBB dysfunction allows inflammatory cell penetration into the 
brain parenchyma, and these insults may be correlated with the acceleration of 
neurological damage (Edvinsson and Povlsen 2011; Dirnagl 2012). Thus, protecting 
BBB integrity during cerebral stroke has a strong influence on preventing cerebral 
damage. However, whether AT1 blockade affects BBB barrier function in vitro is not well 
understood.  
In this study, we hypothesized that candesartan has the potential to protect the BBB 
during cerebral stroke. We have investigated the effects of candesartan on rat brain 
capillary endothelial cell dysfunction induced by an oxygen and glucose deprivation 
model in vitro, and explored the mechanism involved. 
 
Materials and Methods 
 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless 
otherwise indicated. Wistar rats were obtained from Japan SLC, Inc. (Japan). All 
animals were treated in strict accordance with the National Institutes of Health Guide for 




the Nagasaki University Animal Care Committee. Candesartan (Blopress®) was 




Rat brain capillary endothelial cells (RBEC) 
 
Primary cultures of rat brain capillary endothelial cells (RBEC) were prepared from 
3-week-old rats, as previously described (Nakagawa et al. 2007, 2009). In brief, 
meninges were carefully removed from forebrains and gray matter was minced. The 
homogenate was digested with collagenase type 2 (1 mg/ml, Worthington Biochemical 
Corp., USA) and DNase (15 μg/ml) in Dulbecco’s modified Eagle’s medium (DMEM) 
(WAKO Pure Chemical Ltd., Japan) for 1.5 h at 37°C. The cell pellet was separated by 
centrifugation in 20% bovine serum albumin (BSA)-DMEM (1,000 × g, 20 min). The 
microvessels obtained in the pellet were further digested with collagenase-dispase (1 
mg/ml; Roche Applied Sciences, Rotkreuz, Switzerland) and DNase (6.7 μg/ml) in 
DMEM for 30 min at 37°C. Microvessels were separated on a 33% continuous Percoll 
(GE Healthcare, Uppsala, Sweden) gradient. Microvessels were then seeded on plastic 
dishes coated with collagen type IV and fibronectin (both 0.1 mg/ml). RBEC cultures 
were maintained in DMEM/F12 supplemented with 10% fetal bovine plasma derived 
serum (PDS) (Animal Technologies, Inc., Tyler, TX, USA), basic fibroblast growth factor 
(bFGF, 1.5 ng/mL; Roche Applied Sciences), heparin (100 μg/mL), insulin (5 μg/mL), 
transferrin (5 μg/mL), sodium selenite (5 ng/mL) (insulin-transferrin-sodium selenite 
media supplement), gentamycin (50 μg/mL), and puromycin (4 μg/mL) (RBEC I 
medium) at 37°C for 2 days. The culture medium was then replaced with fresh culture 
medium containing all the components of RBEC I medium except for puromycin. The 
cultures reached 80% confluence (Day 4) and purified endothelial cells were collected 
by brief treatment with trypsin (0.05% w/v)-EDTA (0.02% w/v) solution, and were used 
to construct the in vitro BBB model.  
 





Rat cerebral astrocytes were obtained from neonatal Wistar rats. Meninges were 
removed and cortical pieces mechanically dissociated in DMEM. Dissociated cells were 
passed through a 70-μm nylon mesh (BD Falcon, MA, USA) and seeded into cell culture 
flasks. Astrocytes cultures were maintained in culture medium (DMEM supplemented 
with 10% fetal bovine serum). In order to obtain type 1 astrocytes as pure as possible, 
flasks with confluent cultures were shaken strongly by hand to remove microglia. This 
procedure was performed three times during a two-week culture period. The purity of 
astrocytes was checked by immunostaining for glial fibrillary acidic protein (GFAP), and 
the cells were used at passage 2-3. 
 
In vitro BBB Model 
 
An in vitro BBB model was constructed with Transwell® (Corning Incorporated Life 
Sciences, NY, USA) inserts in 12-well culture plates. Endothelial cells (1.5 × 105 
cells/cm2) were seeded on the upper side of the collagen- and fibronectin-coated 
polyester membranes (0.4-μm pore size) of the Transwell® inserts. The in vitro BBB 
model was maintained in RBEC medium II for 1 day, with the medium subsequently 
changed to RBEC medium II containing 500 nM hydrocortisone. To construct a 
co-cultured BBB model, astrocytes (1.5×105 cells/well) were seeded on the bottom of 
the collagen-coated of 12 well-culture plate (Costar, Corning, NY, USA). The cells were 
allowed to adhere firmly overnight. Thereafter, RBECs (1.5×105 cells/cm2) were seeded 




The candesartan stock solution (10 mM) was stored at -20°C, and diluted in medium for 
the experiments. To compare the effects of candesartan on the RBEC monolayer model 
versus the co-culture model, candesartan was added to both the luminal and abluminal 








Cells were transferred into serum-free RBEC medium II, with or without candesartan. 
Following 6 h of candesartan treatment, the medium was exchanged to RBEC medium 
II with or without candesartan and the cells were incubated for a further 24 h. 
 
Oxygen and glucose deprivation (OGD) and Reoxygenation Conditions 
 
Consistent with our previous reports (Hiu et al., 2008, Horai et al., 2013), oxygen and 
glucose deprivation (OGD)/reoxygenation conditions consisted of 6 h OGD and 24 h 
reoxygenation. For 6-h OGD treatments, serum-free and glucose-free DMEM (Gibco, 
Carlsbad, CA, USA) with or without candesartan were added to the BBB model. Oxygen 
deprivation conditions were generated using ANAEROPACK® (Mitsubishi Gas 
Chemical Co., Inc., Tokyo, Japan). For 6-h normoxic groups, serum-free and 17.5 mM 
glucose DMEM with or without candesartan were added to the BBB model.  
Reoxygenation was initiated by adding fresh RBEC II medium with or without 
candesartan after 6-h OGD or 6-h normoxia.  
 
Evaluation of barrier function in RBEC 
  
Transendothelial Electrical Resistance (TEER) 
 
Transendothelial electrical resistance (TEER) was measured using an EVOM 
resistance meter (World Precision Instruments, Sarasota, FL, USA). The resistance 
measurements of blank filters were subtracted from those of filters with cells. The values 
are shown as Ω × cm2 based on culture inserts. 
 
Paracellular Permeability of Sodium Fluorescein 
 
Endothelial barrier function was evaluated by measuring the permeability of sodium 
fluorescein (Na-F, MW 376). To initiate the permeability studies, the medium in the 
luminal chamber of the insert (0.5 ml) was removed and replaced with assay buffer (136 




NaH2PO4, 25 mM glucose, and 10 mM Hepes, pH 7.4) containing 10 μg/ml Na-F. 
Samples were removed from the abluminal chamber at 30 min. The concentration of 
Na-F was determined using a fluorescence multi-well plate reader (Ex(λ) 485 nm; Em(λ) 
535 nm). The permeability coefficient was calculated as previously described (Youdim 




For immunofluorescence, cells were fixed in 4% paraformaldehyde for 20 min and 
permeabilized with 0.1% Triton-X 100 for 10 min. After washing with phosphate buffered 
saline (PBS) and blocking with 3% bovine serum albumin (BSA) in PBS for 30 min., the 
samples were stained with primary antibodies for claudin-5 and occludin (Invitrogen 
Corporation, Carlsbad, CA, USA). All primary antibodies were used at a dilution of 1:200. 
The secondary antibody, Alexa Flour 488 conjugated donkey anti-mouse 
immunoglobulin (Invitrogen Corporation), was used at a dilution of 1:1,000. The 
samples were mounted in Gel Mount (Biomeda, Foster City, CA, USA) and staining was 
assessed using a Zeiss LSM 5 Pascal Confocal laser-scanning microscope (Carl Zeiss 




Cells were lysed using the CelLyticTM M cell lysis reagent supplemented with proteinase 
inhibitor cocktail (Sigma) and centrifuged at 15,000 x g for 15 min. The supernatants 




(Pierce, Rockford, IL, USA). Samples were separated on 4-15% Tris-HCL Ready 
SDS-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA), transferred onto 
polyvinylidene difluoride membranes (Bio-Rad Laboratories), and incubated with 
primary antibodies. Antibodies were diluted 1:2,500 (occludin), 1:5,000 (claudin-5), and 
1:10,000 (β-actin) in blocking solution (1% Perfect-Block, MoBiTec, Germany). 
Peroxidase-conjugated anti-mouse immunoglobulin (GE Healthcare) was used as a 
secondary antibody. To reveal immunoreactive bands, blots were incubated in 
SuperSignal West Femto Maximum Sensitivity Substrate SECL in accordance with the 
manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA) and were 
detected using a FluorChem SP Imaging System (Alpha Innotech Corp., San Leandro, 
CA, USA). 
 
Nitrate/nitrite levels in the RBEC culture medium 
 
To measure the amounts of nitrate (NO2)/nitrite (NO3), culture medium was collected 
after 6-h OGD or 6-h OGD/24-h reoxygenation. The amounts of NO2/NO3 were 
measured using a high performance liquid chromatography (HPLC) system (NOx 
analyzer ENO-10, EICOM, Kyoto Japan) according to Yamada and Nabeshima (1997). 
In brief, NO2 and NO3 in culture medium were separated using a reverse-phase 
separation column (NO-PAK, EICOM) and NO3 was reduced to NO2 in a reduction 
column (NO-RED, EICOM). NO2 was mixed with Griess reagent to form a purple azo 






Intracellular Levels of Reactive Oxygen Species (ROS) 
 
Intracellular reactive oxygen species (ROS) were measured with a CM-H2DCFDA 
(Invitrogen). CM-H2DCFDA is a cell-permeable fluorescent dye which generates 
fluorescence upon reaction with ROS. RBEC were seeded at a density of 5,000 cells 
per well into 96-well plates. After confluency, RBEC were exposed to 6-h OGD or 6-h 
OGD/24-h reoxygenation. Subsequently, CM-H2DCFDA (5 μM) in assay buffer was 
added and further incubated for 30 min. The fluorescence intensity of the probe was 
determined using a fluorescence multi-well plate reader (Ex(λ) 485 nm; Em(λ) 535 nm). 
The values of ROS produced are presented as a percent of control.  
 
Cell Viability  
 
Rat brain capillary endothelial cells (RBEC) were seeded at a density of 5,000 cells per 
well into 96-well plates in culture medium. After exposure to 6-h OGD or 6-h OGD/24-h 
reoxygenation, the number of viable cells was determined using a Cell Counting Kit 8 
(Dojindo Co., Kumamoto, Japan) according to the manufacturer's instructions. The 
assay reagent is a tetrazolium compound (WST-8) that is reduced by live cells into a 








compared using an analysis of variance followed by the Tukey-Kramer post-hoc test. 




To investigate whether candesartan could affect the integrity of endothelial 
monolayers under normal culture conditions, two BBB models, RBEC monolayer model 
and RBEC co-cultured with astrocytes, were treated with candesartan (10 nM) and 
barrier function was measured using transendothelial electrical resistance (TEER). In 
agreement with previous reports, barrier function in cultured brain endothelial cells was 
enhanced by co-culture with astrocytes (control value at 72 h: 150.8 ± 6.5 vs. 264.0 ± 
20.0 Ω × cm2) (Fig. 1a, b). Although candesartan did not affect TEER in the RBEC 
monolayer model, candesartan enhanced TEER in the RBEC-astrocytes co-culture 
model (Fig. 1a, b). 
In order to analyze the potential beneficial effects of candesartan on ischemic 
endothelial damage, RBECs were subjected to 6-h OGD/24-h reoxygenation. 
Endothelial barrier function was estimated by measuring TEER and paracellular 
permeability of Na-F (Fig. 2). TEER was significantly decreased following 6-h OGD/24-h 
reoxygenation compared to normoxia (86.8 ± 2.2 vs. 100 ± 2.1 %; P < 0.05). The 6-h 
OGD/24-h reoxygenation-induced decrease in TEER was significantly suppressed by 
candesartan treatment (86.8 ± 2.2 vs. 97.9 ± 2.6 %; P < 0.05) (Fig. 2a). Disruption of 
barrier integrity was also detected by determining Na-F permeability in RBECs following 
6-h OGD/24-h reoxygenation compared with normoxia (4.81 ± 0.4 vs. 3.17 ± 0.2 x 10-6 




10 nM candesartan produced Na-F permeability similar to the normoxia control value 
(Fig. 2b).  
To examine whether candesartan affects the expression of tight junction 
proteins, which is a factor in regulating barrier function, we performed immunostaining 
and immunoblotting. There were no notable changes in the appearance of claudin-5 
and occludin following 6-h OGD/24-h reoxygenation (Fig 3b, e) compared with the 
normoxia control (Fig. 3a, d). In agreement with immunostaining observations, claudin-5 
and occludin protein levels, determined by immunoblotting, were not altered by 6-h 
OGD/24-h reoxygenation. Although 6-h OGD/24-h reoxygenation did not affect the 
expression of tight junction proteins, alterations in cellular morphology were detected 
following 6-h OGD/24-h reoxygenation. 6-h OGD/24-h reoxygenation induced a cobble 
stone morphology that was not observed under normoxia. Candesartan treatment 
suppressed the effects of 6-h OGD/24-h reoxygenation on endothelial cellular 
morphology (Fig. 3c, f). 
As oxidative stress is a factor that induces cellular damage under 
OGD/reoxygenation, we analyzed the effects of candesartan on the production of 
nitrate/nitrite and reactive oxygen species (ROS). There was no significant difference in 
nitrate/nitrite levels as a result of 6-h OGD (Fig. 4a). Nitrate/nitrite level in the RBEC 
culture medium were significantly higher following 6-h OGD/24-h reoxygenation 
compared to normoxia (0.46 ± 0.01 vs. 0.41 ± 0.01 × 10-5 M; P < 0.05) (Fig. 4b). 
Although candesartan tended to suppress the elevated nitrate/nitrite levels induced by 
6-h OGD/24-h reoxygenation, significant differences were not detected. ROS production 
was significantly higher after 6-h OGD than normoxia (233.9 ± 15.3 vs. 100 ± 13.4 %; P 




additional 24-h of reoxygenation (Fig. 4d). Candesartan did not affect the ROS 
production induced by 6-h OGD. 
Lastly, we examined the effects of candesartan on cell viability following 6-h 
OGD/24-h reoxygenation. There was no significant difference in endothelial cell viability 
among the groups following 6-h OGD (Fig. 5a). In contrast, 6-h OGD/24-h 
reoxygenation decreased cell viability. The decreased cell viability induced by 6-h 




 BBB dysfunction resulting from cerebral stroke causes brain edema formation, and 
increases the penetration of neurotoxic factors into the brain parenchyma. Thus 
improving BBB function during cerebral stroke has a significant potential to prevent the 
progression of neuronal damage. In the present study, we found that candesartan 
prevents BBB dysfunctions in an in vitro ischemia model involving 6-h OGD/24-h 
reoxygenation. Our present observations support previous studies showing that 
candesartan reduces brain damage induced by cerebral ischemia, and attenuates 
learning dysfunction in a rat ischemia model (Lu et al. 2005; Faure 2008; Kozak et al. 
2009). 
 The renin-angiotensin system (RAS) plays an important role in regulating the 
cardiovascular and central nervous systems (Saavedra 2012). There are controversial 
reports regarding the effects of angiotensin II (Ang II), mediated via its receptors (AT1 
and AT2), on the barrier function of brain endothelial cells under physiological conditions. 




permeability (Fleegal-DeMotta et al. 2008; Zhang et al. 2010; Pelisch et al. 2011). 
However, Wosik et al. (2007) indicated that Ang II, secreted by astrocytes, improved 
BBB integrity. Therefore, we examined the effects of candesartan on BBB barrier 
function under normal conditions. Our finding showed that candesartan did not 
strengthen the barrier properties of RBEC monolayers under normal culture conditions 
up to 72 hr. In contrast, candesartan increased TEER in RBEC co-cultured with 
astrocytes. It seems that astrocyte-derived Ang II decreases BBB barrier function, and 
candesartan inhibited this effect in our rodent BBB model. Wosik et al. (2007) used a 
large molecule (FITC-labeled bovine serum albumin) as a permeability tracer, together 
with human brain endothelial cells derived from patients with intractable epilepsy as a 
BBB model. In contrast, we used a small molecule (sodium fluorescein) and endothelial 
cells derived from normal rats. Considering that we could not detect BSA leakage under 
basal conditions in our rodent BBB model (data not shown), it appears that the human 
BBB model has a relatively leaky barrier. Therefore, the effects of AT1 stimulation of 
endothelial cells may have different consequences on the barrier function depending on 
factors such as cell type and cell viability. More studies to characterize AT1-induced 
signaling are required to fully understand these observations. 
Next, to investigate the effect of AT1 blockade under pathological conditions, we 
examined the effects of candesartan on RBEC barrier properties under 
OGD/reoxygenation. We established a pathophysiological in vitro BBB model by 
exposing endothelial cells to normoxia or 6-h OGD/24-h reoxygenation. The results 
showed that OGD/reoxygenation increased the permeability of Na-F and decreased 
TEER. We demonstrated that in this in vitro monolayer model, candesartan (10 nM) 




which suggests that candesartan may protect against deficits in paracellular transport 
following OGD/reoxygenation. 
As TEER and endothelial cell permeability reflect tight junction (TJ) function (Deli et al. 
2005), we examined the effect of candesartan on TJ protein levels using 
immunostaining and western blotting. However, there were no significant differences in 
the expression of caludin-5 and occludin after candesartan treatment. Thus, the effect of 
candesartan on BBB permeability is not associated with changes in the expression of 
tight junction proteins. Although reductions in expression of tight junction proteins lead 
to increased permeability, the expression pattern of tight junction proteins along cell-cell 
borders and the phosphorylation of tight junction proteins are important factors in 
modulating endothelial permeability (Ishizaki et al. 2003; Yamamoto et al. 2008). Since 
it remains possible that candesartan may influence claudin-5 and occludin without 
altering protein levels, further studies are needed. Alternatively, as candesartan 
suppressed OGD/reoxygenation-induced alterations in cellular morphology, it is 
possible that candesartan may affect the cytoskeletal protein actin, because 
rearrangement of cytoskeletal actin is known to affect cell shape and cellular barrier 
function (Prasain and Stevens 2009; Bogatcheva and Verin 2008). 
To examine the mechanism underlying the effects of candesartan on endothelial cells 
during OGD/reoxygenation, we determined cell viability and the production of free 
radicals. Increased free radical production during ischemic conditions could increase 
endothelial permeability (Kaur and Ling 2008; Fraser 2011). Nitrate/nitrite plays several 
roles in cellular physiology, including as a free radical, endothelium-derived relaxing 
factor, and a neurotransmitter (Garthwaite 2008; Kvietys and Granger 2011). 




significantly higher than under normoxia. Although candesartan treatment (10 nM) 
tended to suppress nitrate/nitrite levels during OGD/reoxygenation, significant changes 
were not detected. Similarly, candesartan did not affect the production of reactive 
oxygen species (ROS). Considering that reports have indicated that candesartan 
reduces protein nitration induced by peroxynitrite in an in vitro model (Soliman et al. 
2014), a further study to examine protein oxidation levels during OGD/reoxygenation is 
necessary. In contrast, candesartan improved OGD/reoxygenation-induced cell damage. 
Thus our data indicates that candesartan may maintain barrier integrity in primary RBEC 
cultures under hypoxia-reperfusion conditions by improving endothelial cell viability. 
We could not detect an effect of candesartan on barrier properties under normoxic 
conditions, whereas candesartan improved barrier properties under OGD/reoxygenation. 
These results suggest that OGD/reoxygenation affects the Ang II systems in endothelial 
cells, possibly through increased production of Ang II or receptor modulation.  
Recent reports indicate that several receptors, such as adrenergic, histamine, 
serotonin, dopamine, and angiotensin, exhibit constitutive activity in the absence of 
agonist stimulation (Milligan 2003, Khilnani and Khilnani 2011). Antagonists inhibit 
agonist-induced responses, but they do not have the ability to affect 
agonist-independent constitutive receptor activity. In contrast, inverse agonist binding to 
constitutively active receptors reduces their activity (Bond and Ijzerman 2006). 
Some AT1 receptor blockers appear to act as inverse agonist. Candesartan is 
considered to be an inverse agonist and is different from other ARBs (Yasuda et al. 
2008). Even in the absence of Ang II, AT1 receptors can be activated by mechanical 
stimulation, which would not be affected by AT1 receptor antagonist, but could be 




inverse agonist on an RBEC monolayer model are shown here, where it is thought that 
candesartan, in the absence of Ang II, controlled downstream signaling of the AT1 
receptor. Additionally, another potential mechanism of candesartan-mediated BBB 
protection may be due to activation of the AT1 receptor during OGD/reoxygenation, 
which is blocked by candesartan binding to the activated AT1 receptor. 
 In summary, candesartan inhibits increased paracellular BBB transport under 
OGD/reoxygenation conditions. This mechanism may lead to improved cell survival, 
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Fig. 1 Transendothelial electrical resistance (TEER) in two in vitro blood-brain 
barrier models. Rat brain capillary endothelial cells (RBEC) were seeded on Transwell 
inserts one day before candesartan was added to both the luminal and abluminal sides 
of the inserts. a RBEC monolayers was exposed to 10 nM candesartan under normal 
cell culture conditions. Candesartan did not affect TEER in the monolayer model. b 
RBEC-astrocyte co-cultures were exposed to 10 nM candesartan under normal cell 
culture conditions. Candesartan increased TEER in RBECs co-cultured with astrocytes. 
All data are presented as means ± SEM (n = 8). *P < 0.05, significant difference from 
control. 
 
Fig. 2 Effects of candesartan on barrier function in rat brain capillary endothelial cell 
(RBEC) monolayers under normoxia and 6 h oxygen glucose deprivation (OGD)/24 h 
reoxygenation. Barrier function was evaluated by transendothelial electrical resistance 
(TEER) (a) and sodium fluorescein (Na-F) permeability (b). a TEER was significantly 
decreased in RBEC with 6-h OGD/24-h reoxygenation. Candesartan attenuated the 6-h 
OGD/24-h reoxygenation-induced decrease in TEER. Data indicate the rate of change 
in TEER before and after treatment in comparison with normoxia control (100% = 101.8 
± 3.2 Ω x cm2, n = 9). All data are presented as mean ± SEM (n = 7 ~ 11). *P < 0.05, 
significant difference from normoxia control. #P < 0.05, significant difference from 6-h 
OGD/24-h reoxygenation control. b Na-F permeability was significantly increased in 




reoxygenation-induced increase in Na-F permeability. All data are presented as mean ± 
SEM (n = 9 ~ 15). **P < 0.01, significant difference from normoxia control. ##P < 0.01, 
significant difference from 6-h OGD/24-h reoxygenation control.  
 
Fig. 3 Expression of tight junction proteins in rat brain capillary endothelial cell 
(RBEC) monolayers. The expression of claudin-5 (a - c) and occludin (d - f) was 
determined by immunostaining of RBEC monolayers. Although there was no obvious 
change in the expression of claudin-5 and occludin in 6-h OGD/24-h reoxygenation (b, 
e) compared with cells under normoxia (a, d), 6-h OGD/24-h reoxygenation changed 
the cellular morphology to a cobble stone appearance (b, e). Candesartan (10 nM) 
suppressed the 6-h OGD/24-h reoxygenation-induced changes in cellular morphology 
(c, f). Bar = 20 μm. The levels of claudin-5 (g) and occludin (h) protein expression were 
determined by immunoblotting. No significant changes were detected in each group. 
The blots are representative images from separate experiments. Data are presented as 
mean ± SEM (n = 6). 
 
Fig. 4 Effects of candesartan on the production of nitrate/nitrite and reactive oxygen 
species (ROS). Following 6-h OGD (a, c) or 6-h OGD/24-h reoxygenation (b, d), 
production of nitrate/nitrite and ROS were determined using the Griess reagent and a 
fluorogenic dye, respectively. Although the levels of nitrate/nitrite were not altered by 6-h 
OGD alone (a), 6-h OGD/24-h reoxygenation significantly increased the production of 
nitrate/nitrite into the culture medium (b). Candesartan did not affect the production of 
nitrate/nitrite. All data are presented as mean ± SEM (n = 4). *P < 0.05, significant 




cell (RBEC) monolayers was increased following 6-h OGD. d ROS levels in RBECs 24 
h after reoxygenation were equivalent in all groups. Candesartan did not affect ROS 
production. ROS production is expressed as a percentage of the normoxia control 
values. All data are presented as mean ± SEM (n = 4 ~ 5). **P < 0.05, significant 
difference from normoxia control. 
 
Fig. 5 Effects of candesartan on cell viability in rat brain capillary endothelial cells 
(RBEC). Following a 6-h OGD (a) or 6-h OGD/24-h reoxygenation (b), cell viability was 
determined using a cell counting Kit-8. There was no significant difference in endothelial 
cell viability after 6-h OGD (a). Candesartan inhibited the 6-h OGD/24-h 
reoxygenation-induced decreases in cell viability. Cell viability is expressed as a 
percentage of the normoxia control values. All data are presented as mean ± SEM (n = 
5 ~ 14). **P < 0.01, significant difference from normoxia control. ##P < 0.01, significant 
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